PIL scheme: Govt approves four applications for KSMs/drug intermediaries, APIs
May 31, 2021
Forty six applications with committed investment of ₹5,355.44 crore have been approved so far
The government, on Monday, approved four applications under its production-linked scheme for promotion of the domestic manufacturing of Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs).
According to a Chemicals and Fertilizers Ministry statement, Solara Active Pharma Science Limited received approval for 1,1 Cyclohexane Diacetic Acid (CDA) under the chemical synthesis-based KSMs/Drug Intermediates segment, and Rajasthan Antibiotics Ltd received nod for Meropenem Other Chemical Synthesis Based KSMs/Drug Intermediates and APIs.
Similarly, Dhatri Lab Private Ltd has received approval for Ritonavir and Vital Laboratories Private Ltd for Levofloxacin under the segment of Other Chemical Synthesis-based KSMs/Drug Intermediates and APIs. These firms were se
Pharma Sector: Approvals Accorded Under PLI Scheme For Rs 348 Crore Investment In Drug Intermediates And APIs
A Representative Image
In a boost to local manufacturing and reduce import dependence, approvals have been accorded to 16 applicants under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in the country.
The setting up of these 16 plants will lead to a total committed investment of Rs 348.70 crore and employment generation of about 3,042 by the companies.
The commercial production of these plants is projected to commence from 1 April, 2023 onward, the Ministry of Chemicals and Fertilizers said in a statement.
New Coalition Dedicated To Fostering American Synthetic Biology Manufacturing Launched Today
The SynBio Coalition, Backed by Three Industry Leaders, Says Innovation is Key for American Global Leadership, Job Creation, Greater Security, and the New Green Economy; Pledges to Work with Government, Industry
News provided by
Share this article
Share this article
WASHINGTON, April 14, 2021 /PRNewswire/ Today, three leading synthetic biology companies announced the launch of the Synthetic Biology (SynBio) Coalition (www.synbioco.com) to promote investment and support for the American synthetic biology industry. Synthetic biology is a field of science that involves redesigning microorganisms for useful purposes. It is already being leveraged across many industries, including pharmaceuticals and medical treatments, food and agriculture, plastics, apparel, energy, consumer electronics, and personal and home care items, and is poised to have a significant impact on American economic g
Synopsis
The company is focused on development of green technology especially using a Flow-pump reactor to synthesize intermediates, chemicals in sustainable methods of green chemistry.
Getty Images
Bio-technology startup, Bioneemtec India has begun looking at manufacturing Key Starting Materials (KSM) through its newly launched Flow Pump facility with its in-house technology that will ensure a fast conversion rate and reduce the production cost without any environmental hazardous by-products or residues. We are concentrating on developing key raw materials from this flow reactor pump. We have developed some molecules and are looking to produce Acetophenone which is a major raw material that is used for API (Active Pharmaceutical Ingredient) and intermediates, explained Dr. Menaga Magendran, Managing Director, Bioneemtec India. If we are successful, we can produce it at Rs 400 when we are currently importing it from China at Rs 1700.